In contrast, unlike glucocorticoids, diabetes treatment with high-dose salicylates [5], anti-cytokine antibodies (TNF and IL1β) [2] or gene therapy approaches targeting NF-κB regulatory loops (e.g. A20) [13, 17] do not risk directly inhibiting basal NF-κB activity. The gene discussed is NFKB1; the disease is diabetes mellitus.